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INTRODUCTION
The definition of the word 'minor' according to the Concise Oxford Dictionary1
is: 'comparatively unimportant (for example: minor poet) or in case of Operation:
presenting no danger to patient's Iife'. Consequently, in our discipline, the 'majors'
(histocompatibility antigens) must account for the greatest obstacle in human organ
exchange; a barrier which in all probability was already playing a role in ca 300 AD
when two sibling doctors, Saint Cosmas and Saint Damian, carried out a total leg
replacement. Nowadays even with the use of a new potent immunosuppressive drug,
Cyclosporine A, the renal transplant recipient still benefits from a well matched
organ donor.2
The fact that minor histocompatibility (minor H) antigens are 'allied' to the major
Η antigens probably raises one's interest in them. This is based on the assumption
that major Η molecules serve as salvers for foreign antigens, such as foreign minor
Η antigens, thus triggering an immunological Τ cell response.3
This chapter will deal with the recognition of human minor Η antigens, the genetics
of these antigens at the population level as well as in families, and finally their possible
impact on the outcome of bone marrow transplantation will be discussed. This review
does not pretend to cover all Information regarding the influence of non-MHC antigens
on the outcome of organ transplantation, but rather reflects a summary of our own
cellular immunological in vitro studies in relation to bone marrow transplantation
in man in particular.
INTRODUCTION TO AND RATIONALE OF THE STUDY
It is now 49 years since the first human bone marrow transplantation was carried
out.4 In the 1950s, the first series of clinical applications of bone marrow grafting
was reported.5'6 Thanks to Mortimer Bortin, a compendium on the results of the
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first 203 human bone marrow tiansplants performed as therapeutical treatment ol
scverc dplastic anaemia, leukaemia and immune deiitiency disease became available
in 1970 7 Although, the graft versus-host (GvH) reaction histoncally dates from early
this Century,8 the high numbei of deaths in the latter report, was not attnbutable
to GvH disease
Notwithstanding Ceppellmi's Statement in 1967 'there IS httle doubt however that
the motivation of Nature in selecting for a genetic polymorphism of this complexity,
was not an α priori hostibihty against transplantaüon surgeons',9 lt is clear that in
an artificial Situation, such as organ transplantation, the major Η antigens function
as a major transplantation barner and thus play an important role in the survival
of transplants and patients Consequently, improved success in bone marrow
transplantation was reported when matching for the HLA antigens was taken
into aecount 10 Between 1975 and the present day, the long-term results of allogeneic
bone marrow transplantation have greatly improved due to the use of HLA matched
sibhngs as marrow donors, advanced pretransplant chemoradiotherapy, the use
of potent immunosuppressive drugs as prophylaxis, better antibiotics and Isolation
procedures
Despite the promising advances, the Overall results achieved so far are still
not completely satisfactory Graft versus host Disease (GvHD) affects (despite the
selection of HLA identical sibhngs as bone marrow donors) approximately
20-70 percent of the patients depending on their age " 12 The aetiology of GvHD
presumes that immunocompetent donor Τ cells are reaetmg against the host
tissues Thus, when endeavounng to prevent GvHD development, donation
of marrow deplcted from mature Τ cells has become a frequently used regimen
Unfortunatcly, this treatment also has lts drawbacks Graft failure or rejeUion
as wtll as recurrence of the original disease have been leported as major
eomphcations following Τ lymphocyte depleted bone marrov transplant n 14 The
severe, and in some cases fatal comphcations following these marrow transplants
justify the search for at least one of the obstacles to successful bone marrow
transplantation
In human transplantation, donors and recipients are routinely screened tor
Identification of the major Η System, therefore GvHD and rcjection may be caus^d
by the dispanty of the produets of the so called 'minor' Η Systems, ι e
histocompatibihty antigens other than those coded for by the MHC
Skm grafting expenments in the mouse demonstrated the presence of a large number
of histocompatibihty antigens uoded for by multiple loci scattered all over the genome
1 hey show distinguishable patterns in ehciting allogeneic reaction, skin grafting over
a multiple minor Η barnei demonstrates a graft rejection time eomparable to those
that differ only at Η 2 1S l 7
Prior to the detection of the possible involvement of human minor Η antigtns
in the development of GvHD aftei HLA genotypically identical bone manow
grafting,18 convincing results weie reported in the mouse demonstrating that, using
congemc stiains of mice, incompatibility for non Η 2 antigens alone can lead to a
high rate of GvH mortahty u 2I Moreover, the Τ cells causing lethal GvHD atross
minor Η barners appeai to be Η 2 iestucted Thus Γ cells re^ponsible for induction
of GvHD to minor Η antigens do not respond in vivo to the samc minor Η antigens
picsenled on Η 2 different cells 2 2 n
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CELLULAR IMMUNOLOGICAL IN VITRO STUDIES
OF HUMAN BONE MARROW TRANSPLANTATION
Figure 3-1 functions as a guidehne according to which I will treat the major effects
resulüng from bone barrow transplantation, lllustrated with, as far as possible, the
results of our in vitro studies First, the studies deahng with graft failure/rejection
will be discussed Second, the complication of GvHD will be examined, exemplified
with in vitto studies reflecting the graft-versus-host attack Finally, I would hke to
touch bnefly on the possible 'graft-versus-leukaemia' (GvL) effect
PATIENT DONOR
RECIPIENT
with
donor cells
DONOR Τ CELLS
RESPONSIBLE FOR
GvHD
DONOR Τ CELLS
RESPONSIBLE FOR
GvL
3-1. Cellular immunological in vilio studies of human bone marrow
iiansplantation AA = aplastic anaemid, GvHD = graft-veisus host disease, Gvl =giatt-
\trsus lcukaemia
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The Male Specific Antigen H-Y
Ct'llular Recogmtion
Our involvement in human minor Η antigens started in 1975, virtually by
eoincidtnce On one hand we were inteiested in mutually cytotoxie Τ celi (CTI )
icaüivities betwecn Hl Α identical siblings in vitro, and allei in vivo sensiti/aüon 24 l s
On the other hand, a ehnical so ealled 'no takc' obseivation aftcr bone mairow
gralling, donaled by a male sibling donor to his HL Α gcnotypieally identieal
sisttr, was reported to us Tortunately, this dinieal event led us not only to
the first dcmonstration in man of thc partiupation of the Hl Α molctulcs in
the inteiaction of Τ teils with foreign antigen, but also brought us into the
mysteiious world of minor transplantation antigens of whith the male spcufic
antigen Η Υ is the lar easiest and also the most extcnsively minor Η antigen
studied 1S1(
I he Inst repoit of Η Υ as a transplantation antigen is an untitled tommumcation
by L-ithwald and Silmser in 1955 These authors observed that within (wo inbred stiams
ol nuce, most ol the male to iemale skin gratts were rejeeted, wheieas tiansplants
made in other sex eombinations nearly always sucteeded 27 The tcrm Η Υ antigen
was mtrodutcd by Bilhngham and Silvers28 beeause the male spetilic antigen can
funetion as a classical transplantadon antigen responsible (oi homogial! icjection
An important Step in the retogmtion of the H-Y antigen in vitro, using Η Υ immune
spieen cells obtamed liom in vivo immuni/cd Iemale mite, was repoitcd by Goidon
et al ' ' In vitio cell mediatcd cytotoxie lesponses to the male spetilie antigen Η Υ
wert found to be Η 2 lestneted, ι e CTI s recogni/e loieign antigens, such as Η Υ,
only when they aie presented to the C Γ1 s on cells which shaic some homology ol
the Η 2 icgion as expressed on the ellettor C Π s Snnilarly, the ictognition ol othei
minor Η antigtns by C TI s is also MH( lestnetcd '"
Results in View of Climtal Lase\
Returmng to oui clmical easc, in vitio analysis ol the posttransplant penpheia l
blood lymphocytes (PB1 s) of the Iemale paticnt (Hl Λ phenolype Hl Α Λ2, Λ2,
B44, B60, C w l , Cvv5, DR4, DRw6) showed unambiguously stiong CTI icsponses
speeilie foi male HL Α A2 positive target teils ls 1( Whether the Η Υ spceifie C l 1 s
attually mediated thc allogiall rejcttion, we do not know It must bt icmaiked,
howtver, that most probably the Iemale palicnt, who was sulleiing liom scveie aplaslic
anacmia, had becn scnsiti/ed to the Η Υ antigen ρποι to ( lanspianfadon (htough
multiple (niainly male) blood tianslusions and picgnancics This assumption is based
on out substqutnt obseivations As shown in Fable 3 1, PB1 s denved l iom loui
additional tases showtd, altei /// vitio icstmuilalion with H l Α identital male tt l ls
txat t ly the same phenomenon, nanicly Hl Λ rcstrietecl ( A I , A2 and/or B7)
anti H Υ ty totoxi t l teil activity In one paticnt (ι t ( ase 5, l a b l e 3 I), HK
Η Υ specific Hl Α Β7 r e s lnücd tytotoxit i ty was de te t t td shortly alter an atutel>
i t j t t t cd kidney donated by an HI Λ identical male sibling (unpublishtd oDscivation)
In tncumsidiices similai lo ours, othet investigators also des tubed the picsence ol
Hl Λ i t s l t i t t t d H Υ dnected tytotoxit i ly " p
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lable 3-1
MHC Restncted Cytoloxic Τ Cell Responses Against the Μιηοι Η Antigen Η Υ
HLA Typing CTI sPaticnt/Diseasc
1 AA*
2 AA
1 AA
4 AA
c
CTI s Denved From
9 post bm giafling
9multi transfused
9multi tiansfused
9 multi tiansfused
9 post renal transplant
HLA (A2), A2, B44, B60
HLA (A2), A3, B60, B62
HLA (A2), Α28, (ß7) B62
HLA ( A T ) , A2, B8, B61
HLA A2 A2 (βτ), Β13
Ο
MHC restnctmg antigens
Aplastic anaemia
Althoügh in our first ease we formally could not prove that the Η Υ specihc CTI s
actually mediated the rejection ot the male allograft, vcry retently we have been
Lonfronted with a case with a fatal outcome, in which anti Η Υ CTLs weie most
piobably mainy responsible for graft rejection It concerned a multitransfused female
patient suffenng from myelodysplasia alter treatment for Hodgkin's disease In vitro
analysis demonstrated the presence of HLA-A1 restntted anti Η Υ CTI s (1 able 3 1,
( ase 4) Since the father appeared to be the only HLA compatible related donor, he
was the obvious choice (despite, unfortunately, the presence of patient's prettansplant
inti Η Υ CTLs) Notwithstanding intensive pretiansplant immunosuppicssive
tiuitment and the donation of Τ cell depleted marrow there was no lecovery ol the
patient's bone manow haematopoietic tunction (Voogt et al , ms in preparation)
With hindsight, the choice of an unrelated HLA identical (or comnatible) (emale
bone marrow donor might eventually have led to a less diamatic result The
tonsideration of choosing in favour of an unulated — or even a partially HLA
nusmalched donoi—will be treated in more detaii elsewhere in this chaptei
Inlerestingly, it IS not only very recent reports," M but reports sin< e 1977,1S which
have pointed towards sex mis-match as oneof thensk fattois assouated with GvHD
oi icjection According to the most recent data collected worldwide and evaluated
b> the Advisory Committee of the Inteirational Bone Manow Registiy " 1 4 male
lo lemale, and female-to male transplants have a high chance of rejection respectivcly
d\HDin acute myelogenous leukaetma(AML), acute lymphoblastic leukaemia (AI L),
Juonic myelogenous leukaemia (CML) and severe aplastic anaemia (SAA) Wiih
Special legaid to marrow treatment in the latter disease, I think it might be helplul
io a certain extent to be awaic ol the apparcntly lairly high incidence in vilio ol CTI s
ihicetcd against the male specific antigen H-Y Λ rcpoit on the piesence ol anti Η Υ
lAiotoxiuty in an untiansiused 11 yeai old female patient with SAA, luither
siiengthens this point "'
1 hc clinical relevance of the Η Υ alloantigcn on the lesults ol human kidney allogiaft
Mansplantation has also been determined Α retrospective study showed a significant
dilkience between HLAA2 females receiving HI Α Α2 male kidneys and non
Hl Α A2 females receiving non HLA A2 male kidneys, 2 ycais aftei tiansplantation
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Male allografts from HLA A2 positive donors in HLA-A2 positive females survived
for a significantly shorter time than non-A2 male kidneys in non-A2 female
retipients "
Perspectives
To elaborate on the assumption that minor Η antigens such as H-Y do indeed play
a role in the success of graft exchange between HLA identical siblings in general and
in Τ cell depleted marrow in particular, we investigated the expression of this minor
Η antigen on haematopoietic progenitor cells (HPC). For this purpose, an in vitro
cellular cytotoxicity assay with bone marrow cells as target cells has been
developed 3 8 In bnef, in vitro sensitized HLA-A2 specific CTLs were incubated with
bone marrow mononuclear cells derived from, for example, HLA-A2 positive or
HLA-A2 negative donors Complete Inhibition of growth was observed in the myeloid,
erythroid and multipotential HPC from the HLA-A2 positive individual,38 whereas
normal outgrowth of HPC cultures was observed in the bone marrow cells from
HLA-A2 negative donors
Naturally, the next step was to investigate whether or not the H-Y antigen IS
expressed on human HPC The results of these expenments show that indeed
the H-Y antigen is expressed on HPC 3 9 These observations support the notion that
the minor Η antigen H-Y is by and large hkely to play a role in the failure of (stable)
marrow engraftment, particularly in the graft failure of Case 4 as discussed in the
previous section
Little is known about the nature and exact function of the histocompatibihty
antigen H-Y Recent examination of sex-reversed humans by combined analyses of
different sets of Y-DNA probes and H-Y specific CTLs revealed that the gene for
Η Υ maps to the long arm or centromenc region of the human Υ chromosome 4 0
Hopefully, we will reach the State in which we can study which peptide(s) (obtained
either by cleavage of the H-Y gene product or chemically snythesized) forms the
lmmunogenic complex with the MHC class I (HLA-Al, -A2 or -B7) molecules as
recogni/ed by the CTLs Thereupon, one could think of making antibodies against
such peptide(s) which could block the specific cytotoxic activity as well ds neutrahze
the intact H-Y protein so that the individual is protected from unwanted H-Y d'retted
cytotoxicity
The interaction of the Η Υ antigemc peptide(s) with lts 'salver' is also interesting
In the light of our fmdings the H-Y antigen preferentially binds to the HLA-A2
molecule Therefore analysis of the epitopes on the HLA-A2 molecule required foi
cellular recogmtion of the H-Y antigen has been tarned out These studics led to
the observations that alloimmune HLA-A2 specific CTLs41 n as well as HLA-A2
restncted H-Y specilic CT1 s41 can distinguish between several, yet serologically
identical, HLA-A2 molccules Latclv, additional Information has become available on
the more precise location of the amino acids on the HLA A2 molecule involved in the
recogmtion by CTLs Combined investigations (rcsulting from a collaborative elfort)
oi the HLA A2 'vanant' molecules al the molecular and at the funetional level,
demonstrated thdt arnino acid changes at position 43 and in the residues 145-157 (ι c
celluldi defincdsubtypesHI Λ-Α2 2 and HLA A2 3)leadtothelossepitope(s)necessaiy
for dssouative recogmtion of the H-Y antigen by Hl A-A2 leslncted ClLs " 4 4
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Interestingly, a Single amino acid change from phenyalamne to tyrosine at position 9
in the heavy chain of the HLA A2 molecule (1 e cellular defined subtype HLA A2 4)
does not affect the recogmtion of H-Y by HLA A2 restncted CTLs 4 3 Recently, (he
crystal structure of the punfied HLA A2 molecule provided us with Information
on the differential functions of the amino acids in the different domains of the
HLA-A2 molecule 3 According to the latter authors, lesidue 9 IS one of the positions
located in the binding Site region for processed antigen and thus might be involved
in the binding of the H-Y peptide(s)
This assumption is extremely interesting because of the following observation
three different HLA-A2 molecules ι e 1) M7 HLA-A2 2, amino acid changes
at positions 43,95,156 (ref 45), 2) AM HLA-A2 2Y, amino acid changes at
positions 9,43,95,156 (ref 46) and 3) Cla HLA-A2 4, amino acid changes at position 9
(ref 44) have been analysed with the HLA-A2 restncted H-Y specific CTLs
Absence of recogmtion was only observed when male donor M7 was tested as target
cells4 7 The sole difference between M7 and AM is an additional amino acid change
at position 9 in AM which is absent in M7 Despite the hmited Information which
is available so far, these results further strengthen the postulated interaction
of position 9 in the at domain of HLA-A2 molecule with antigen The amino acid
change at position 9 from Phe to Tyr is identical between Cla and AM but is the
difference between AM and M7 These data suggest that tyrosine is a candiddte for
the binding of H-Y into the groove of the top of the HLA-A2 molecule
The 'Other' Minor Histocompatibility Antigens
l'olymorphic Blood Genetic Markers
Before discussing the method of detection, identif lcation and genetics of our minor
HA antigenic System and lts possible influence on the development of GvHD, the
involvement of other putative 'minor' non-HLA histocompatibility antigens in GvHD
should be mentioned Sparkes et al 4 8 reporteü on a significant correlation between
compatibihty for the blood group System MNSs betwen donor and recipient and
CivHD, incompatibility for this System may result in GvHD Similaily, De Gast et
dl A9 studied the association between 22 polymorphic blood genetic markers and
dvHD Three (ι e rhesus, MNSs bloodgroup and acid phosphatase) of the 22 markers
appeared to be involved in GvHD Mismatching lor all three markers showed an
additive effect and significant correlation with GvHD
The Minor Histocompatibility Antigens 'HA ', the origin of HA-1
Again, a chmcal case opened our eyes to the first demonstration in man of possible
involvement of minor Η antigens (other than H-Y) in the development of GvHD
1 he sccond part of the section on cellular lmmunological in vitro studies of human
hone mairow transplantation will deal with GvHD (see Fig 3-1) The occurrence of
ι severe GvHD in a bone marrow-transplanted male AML patient piompted us to
nncstigate the in vitro cytotoxic activity of the patient's posttiansplantation
hmphocytes The patient had becn transplanted with bone manow from an
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HL Α ldentital lemale sibhng donor His chnital retovery, however, was eomphcated
by severe ehronie GvHD The initial expenment demonstrated that the posttransplant
lymphocytes had strong eytotoxic activity against the patient's own /vetransplant
lymphocytes but not against the lymphocytes of his HLA identical donoi l 8 This
obseivation in ltself Supports the notion that whatever the target determinant
recogmzed by the latter CTLs, the HLA genotypically identical donor and recipient
differed for lt
From additional analysis of the patient's posttransplant CTL activities, lt became
appaient that the antigen (which we designated minor Η antigen HA 1) was not only
piesent on the patient's own pretransplant cells, but could also be detected on
lymphocytes from two out of three haplo identical siblings as well as on the
lymphocytes of the parents, and also on lymphocytes from a laige number of unrelated
healthy individuals The antigen HA 1 could be recognized by the patient's
positransplant CTL only if one of the patient's HLA class 1 antigens was present
on the target cells 5() Consequently, HA 1 IS recognized in an MHC restneted
fashion, an event comparable to the recogmtion of Η Υ and similar to that desenbed
in the mouse (see ρ 30)
Since strong anti minor Η antigen cytotoxic activity was observed in a patient
suffenng from severe GvHD after HLA identical bone marrow transplantation, it
was reasonable to assume that there might exist a correlation between both in vivo
and in vitro observations Based on this concordance, we feit it was justified to contmue
our search for non HLA antigens and their possible role on the outcome of bone
marrow transplantation For this purpose we used the simple, yet labonous, method
as outhned in the following section
Methodology
The basic idea of generating anti host CTLs with specific cytotoxic activity for
non HLA antigens is based on the assumption that posttransplant (i e donor) cells
when sensitized against the patient's own pretransplanl cells, are directed against host
specific target struetures, such as minor Η antigens, which are absent Irom the donoi
cells 7 his supposition is plausible since our sludies have been carned out with nutenal
obtaintd from HI Α genotypically identical bone marrow donor and lecipient
combinations
The protoeol, which we commonly use, enables not only the genoration of anti
host CTLs posttransplantation of bone marrow, but also the estabhshment and
expansion of minor Η antigen specific CTL hnes The success of this was due to a
crucial, in fact logical, cultunng pohey and an imphcit confidence in sueeeeding
Ptupheral blood lymphocytes (PBLs) taken from the patients shortly after bone
marrow transplantation look disastrous So, the tnck is to prime the 6 day old
lesponder/stimulator ccll cultuies with specific stsmulator cells and highly punfied
intcrleukin 2 (HP 11 2) for 3-4 days (see I ig 3 2) This restimulation is just suflicient
lor the few surviving cells lo recover and to Start prohfeiating The HP 1L 2 is
prcferable to reeombinant IL 2, because it contains small amounts of extra possible
growth factors fherealter, the effector cells are regularly fed with, most prcferably,
the original stimulator cells (or if not available, lymphocytes from Hl Α ldtntical
unrelated healthy individuals) and Τ cell giowth factor(rCGI) Since each individual
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Responcer cells
post-transplant
patient's
lymphocytes
Stimulator cells·
pre-transplant
patient's
lymphocytes
6d.
restimulation
with: HP.IL-2
& spec.stim.cells
feeding
with TCGF
& spec.stim.cells
9d. 13d. 18d. 25d 32d.
CML assay and storage of effector cells
Figuse 3-2. Flow chart for generation of anti-host CTLs
CML = cell mediated lympholysis HP IL-2 (highly punfied inter
leukin-2) and TCGF (T cell growth factor) are both commercially
available from Biotest HP IL-2 IS used in the first restimulation,
thereafter TCGF is added for growth promotion Recommended
cell numbers at day 0 mimmum of 2 106 responder cells and 2 106
stimulator teils in 2 ml of culture medium
Lcll-hne has Us own growth kinetics, the optimal effector cell yield and cytolytic
activities can only be achieved by paying attention to each effector cell combination
individually Onte reasonable growth is obtained (in general between 12 and 20 days
of culture), the effector cells are first tested for specific ~ytotoxic activity ι e patient's
prttransplant lymphocytes Subsequently, further expansion of the CTLs is provided
b> the alternate addition of feeder cells and TCGF Specific cytotoxic Τ cell activity
is measured by the use of the cell-mediated lympholysis (CML) assay pieviously
uYscnbed in detail 5I
inti-host Cytotoxic Τ Cell Activities
Next, we aimed at both coniirmation and extension of oui first results regarding the
possible impact of polymorphic genetic Systems other than HLA on the development
ol GvHD in man For this purpose, we investigated posttransplant lymphocytes from
a senes (Λ = 28) of recipients of HLA identical bone marrow grafts for the presence
o! anti-host CTL activity Posttransplant lymphocytes from 17 out of 21 patients
sulfenng from GvHD demonstrated CTL activity (Table 3-2), which was directed
mamst patients' own pretransplant lymphocytes Host directed CTL could so
teil be demonstrated in all (except one) patients suffenng from chiornc GvHD
I uilhermore, in five out ot eight patients with acute GvHD, anti host CTL activity
was also observed One of the lattei CTL populations (designated as 'anti HA 3'
< IL s) has been analysed extensively and will be discussed in the following sections
I he remaining foui anti host CFL populations generated with posttransplant PBLs
I1 om patients with acute GvHD and those geneiated in the two patients without GvHD
u <- uirrcntly under investigation We do not know yet whether the cytotoxic eftector
^11 populations and the target struetures they are directed at die diffeient in the acute
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lable 3-2
Anti host Cytoloxic Γ Ccll Aclivity after HLA Identical Bonc
Manow Graiting
Bonc Marrow Reupients
No GvHD
Aculc GvHD
Chronic GvHD
Anti host
Yes
2
5
12
Cytotoxic Activity
No
5
1
X - 8 62
ρ 0 00134
patitnts or those suffenng from chronic GvHD At the moment we cannot also piovidi
Information on the specific reaetivity of the populations observed in patients withou
any clinical signs of GvHD, except for one donor/recipient combination in th(
'no GvHD' group where an HA-3 incompatibility was observed (see subsequen
settions where the inverse torrelation of the HA 3 antigenic determinant with the
oecurrence of GvHD will be discussed)
At present, we are also attempting to gain insight into the kmetics ol the in vitic
anti host responses, betause to date our search lor anti host CT1 activity has beer
hmited to one posttransplant ( ± 4 0 days) bleeding date The appearance and eventua
dccline of both prohferative and cytotoxic <mü host Τ cell activities have beer
systematically analysed The results so far show that host-dnected Τ cells can bt
detected from 25 days to 25 months after bone manow transplantation, the lattei
long lasting anti host CTLs was observed in a patient suffenng from chconic GvHD
(van Eis et al , manusenpt in preparation)
The results of the anti-host CTl activities posüransplantation oi bone mai row can
bc summari7ed as follows lirst, posttiansplant anti host CTl attivity can be gencrated
in patients suffenng from chronic GvHD As far as analysed, these activities an
extiemely high and long lasting Second, m five out ofeight patients with acute GvHD
anti host cytotoxic responses were lound, the latter patterns however are rather variable
in appearance and activity Third, anti host Τ cell activities can be present in some
patients without GvHD and thus do not umquely appear in patients with GvHD
suggesting that anti host CTL are not the sole mediators of GvHD These prclimmaiy
Undings in man are in hne with results reported in mice S2 Finally, that host directed
Γ cell activities in patients without any clinical signs of GvHD and also in patients
suffenng from acute GvHD only are observed, louches upon an interesting lssue,
numely η ma> lead us to the identil ication of the populations responsiblc for ehciting
the graft versus lcukaemia (Gvl ) reaction This will be discussed later
Genetics oj the HA Antigenic System
Similar to the initial anti host specific CTLs Ή Α Γ (as discussed previously), wc
next endeavoured to uncover the specificity oi the ta\gel structuies lecogm/ed by
some ol the anti host CTLs (see Fable 3 2) 1t IS worth noting that such CTLs can
be denved from uther male or female patients suffenng from different haematologic
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lable 3-3
MHC Restncted Cytotoxit Τ Cell Responses Against Minor Histocompatibility Antigens
Minoi Histocompatibility
C II s Denved I rom HLA Typing CTLs Antigens
I AML o-post bm graftmg HLA (A2), A2, ffi), Β (62) H A I
2 AA 9 post bm grafting HLA AI, (A2), B7, B8 HA 2
1 AML σ post bm grafting HLA (Aj) , AI 1, (ßg), Bw60 HA 3
4 CMI 9 post bm gralting HI Α (A2), AI, B18, B44 HA 4
5 AML 9 post bm grafting HLA (A2), Α29, 1^ 344), B49 HA 5
( JMHC restrictmg antigens
mdlignanues pnor to bone marrow transplant (Table 3-3) Five (including HA 1) out
ol the 28 anti-host CTL populations (see Table 3 2) underwent comprehensive analyses
dt the population Ievel as well as in famihes Comparable to HA 1, anti host CTLs
duived from the second, third, fourthand fifthpatient werefoundtobedirectedagainst
minor Η antigens, designated HA-2,3,4,5 respectively, requinng seif HLA class I
uittgens for thetr recognttion These conclusions are based on the reaction patterns
t\lnbited by CTLs HA-1 to HA-5 against a panel of unrelated healthy individudls as
shown in Table 3 4 The common denominator of HA 1,2,4 and 5 speufic CTI s ts the
prcfercntial use of the apparently populär MHC class I restnction molecule HLA-A2
Notwithstandmg, likewise the HA-1 speciftc CTLs, the HA-3 and HA-5 spectftc CTLs
showcd lysis of target cells which camed another seif MHC class I molecule (HLA AI,
138 and B44 respectively) We have, as yet, no data to indicate whether or not the
minoi Η antigens which are seen in association wi'h HLA A2 are dtstinct from tho->e
1 n.ogni7ed by HLA-Al or -B8 (in the case of HA 3) or Hl A-B44 (in the case of HA 5)
dnectedCTLs Table3 4showsthefrequencydisinbution ofthefourHLA A2restncted
C Γ l s in a reasonable number of healthy unreiated HLA-A2 positive individuals 1t IS
Uuir (hat the minoi Η antigens HA-1,2,4 and 5 are found at a high frequency in the
1 indom population The same applies to the minor Η antigen HA-3 (data not shown)
The piesumption that the anti HA-1 and HA 1 CTLs are in fact recognizing one
dctetminant and that the anti-HA-4 and HA 5 CTLs are recogni7ing a second
dcteiminant, allehc to HA-1 and HA-2, is untenable as will be clear from the inspection
ol fable 3-4 Moreover, one ieels inclined to conciude that the anti HA 1 and HA 2
C ! 1 s (r value = 0 44) but especially the anti Η A-4 and anti Η Α 5 CTLs (/ value = 0 87)
might recognize identical minors Despite their apparent identity, there aie a number
ol uiscs where the CTLs typ; the same target cells differently Cold taiget Inhibition
i.\pcnments, perfoimed wit'i the effector cell-hnes, conhrmed this at least with regard
10 iht incapabihty of HA 1 or HA-4 cold target cells to inhibit HA 2 speufic cytotoxic
ictivity (Fig 3 3) Cold target Inhibition studies foi HA 4 versus HA 5 as well as
m.ilyscs at the clonal Ievel are presently undertaken to prove or disprove their identity
\i tIns stage we conciude that the antigen HA 1 is different from HA 2, and that both
HL different from the antigens HA 4 and HA-5, lt is highly probable that HA 4 and
HA 5 are identical
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Fable 3-4
Minor Histooompatibihty Antigens CTL Typing in HI Α Α2+ Individuais
η HA 1 HA 2 HA 4 HA 5
70 + + + +
1 + + -t -
3 l- + - +
21 + + - -
3 + - + +
1 - 4 + +
1 - + + -
1 - + - +
11 - + - -
6 - - + +
"1 _ _
% 81 90 68 69
+/- -/+ - / - r
HA 1/HA 2
HA 4/HA 5
HA 1/HA 4
HA l/HA-5
HA 2/HA 4
HA 2/HA 5
95
80
74
76
73
75
3
2
24
22
36
34
14
4
8
8
9
9
9
35
15
15
3
3
0 44
0 87
0 32
0 34
0 02
- 0 0 1
/ — χ Vn, all χ were calculaled with Yates' correction No mcidenccs of cytoLoxiuty have beoi
obtained against HLA A2 negative (n - 70) target cells The genotype frequencies of HA 1, 2
4 and 5 wilhin the HLA A2 positive population IS 56 percent, 69 percent 43 percent and
45 percent lespectively
In Order to gain msight into the genetics of the HA antigenic System, vve investigated
the relatives of the bone marrow donor/recipient combinations (between whom wc
generated the ^everal HA specific CTLs, see Table 3-2 and 3-3), with HA-1 to HA-5
specifit cytotoxic Τ cell reagents The pedigree of one of these five famihes is given
in Fig 3-4 The reactivity patterns in these patients' famihes (and also in other
randomly chosen famihes, Goulmy et al , ms in preparation) showed clearly segregation
of the HA antigens They also demonstrate that HLA identical sibhngs tan diffet
lor the HA antigens I or example in the family of patient HA-4 (Fig 3-4), healthy
sibhngs 09 typed differently from her HLA identical sibhngs 04, 06 and 10 Thest
latter sibhngs typed identically for HA-1,2,4 and 5 among each other, likewise sibhngs
05 and 11 O( interest is that the HA-2 antigenic determinant which is piesent
on the mdternal cells (00) is apparently lost in the third generation (i e 82,
Fig 3 4) } inally, as exemphfied in Fig 3-4 and observed in all bul one (i e HA-3)
donor/recipient combinations which led to the creation of the HA specific CFLs,
the donors and reupients differ for more than one minor HA antigen Consequently,
C F l s geneidtcd fiom posttransplant lymphocytes fiom patient 4 leading to the
cytotoxic Τ cell population designated as HA-4 specific CTI clones (Fig 3 4) must
also be present directed against HA-1 and HA-5 The panel analysis (Table 3-4)
performed with the bulk eflectoi cell populations HA 1,2,4 and 5 is consistenl
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HA-2 specific CTLs
80
60
40
20
- — "" ~ ^ —
^ ' ' ' " ' '
_» cold HA-1
+
2
-* cold HA-1+2
-x cold HA-1+2~
-"· hot HA-1~2+
j cold HA-1+2*
> cold HA-1 2
(spec.)
-* cold HA-l+2+
5 10 20 40:1
effector:target ratio
HA-2 specific CTLs
80
60
20
cold HA-2_4.
/cold HA-2_
'/cold HA-2
' cold HA-2 4
10 20 40:1
effector:target ratio
I i)jure 3-3. Cytotoxic Γ cell activity with spccificity for the HA-2 antigen; competitive
Inhibition expcnmcnts Hot : cold target ccll ratio IS 1 : 10.
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with the latter notion, ι e the HA-1 specificity IS present in the HA-4 effector cell
bulk population
Evaluating the analyses in families, in the population, and the cold target Inhibition
studies carned out so far, the propositions for the HA antigenic System are as follows
the HA 1 antigenic specificity is included in the HA-2 'specific' CTLs but is different
from the HA-2 antigenic determinant and, both are different from HA-4 and HA-5,
the latter two are most probably ahke Α pronouncement upon the possible location
of the genes coding for the HA-1,2,4 and 5 productsis, at this point of investigation,
not justified Current exammation of a large number of families will hopefully enable
us to answer the question of whether or not they are linked to HLA
Results in Relation to the Clinical Situation
Based on the observation that host-directed CTLs specific for minor Η antigens
tan be generated posttransplantation of bone marrow in patients suffenng from
GvHD, a retrospective analysis has been performed to study the relationship between
HA incompatibilities and the occurrence of GvHD in a senes (n = 87) of HLA identical
donor/recipient combinations The five well defined minor Η antigen specific CTLs
(HA 1 to HA 5) were used as cellular typing reagents Table 3-5 demonstrates that
incompatibilities for HA-1,2,4 and/or 5 between bone marrow donor and recipient
oceurred preferentially in the group of patients suffenng from GvHD In some (n = 4)
HLA A2 positive pairs, HA-1,2,4 oi 5 was absent in the recipient, but present in
Ihe donor These 'reverse' incompatibilities can play a role in GvHD, and will always
influence possible graft rejection
Concentiating on the HLA-Al restncted mmor Η antigen HA-3, our studies to
date do not imply a correlation of the HA-3 antigen with the occurrence of GvHD
Despite the fact that the HA-3 specific CTLs were onginally generated in a paticnt
sulfenng from acute GvHD, the retrospective typing analysis in HLA AI positive
pairs (Table 3 5) demonstrated HA-3 inco'npatibility between donor and recipient
in patients without any clinical signs of GvHD aftcr tiansplant (n = 3) Moreover,
the Ihree patients suffenng from acute anj/or chronic GvHD which typed nonidentical
I able 3-5
< cllular Typing for Human Minor Η Antigens with MHC Restncted Minor Η Antigen SpcciliL
C 11 s (a relrospcctive study)
HLA Λ2 Positive Pairs Hl Α AI Positnc Paus
Typing for HA 1,2,4 and 5 Typing foi HA 3
Donoi/Reupient Pairs Identical Non identical Identical Non identical
Kiupicnts without GvHD
Ktupicnts with acute GvHD
lUupients with chronic GvHD
I IIL iuiinbcis in paicnlhcses indicate the numbei of bone manow donor/recipient pairs in whieli
IIIL HA incompatibility was piesent on the donor cells By subtiatling these numbtrs, the
minor Η antigen incompatibilities HA 1 2,4 and 5 and GvHD are signifieantly associattd
1/ 0 042 il calculatcd as gioups without, acute and thronit sepantely)
paus used foi geneiating the HA 1 to HA 5 specific CTl s are not included
14
20
10
2(2)
8(2)
6
7
8
6
3
HD
2(2)
4 4
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with their donor for HA 3, were mismatched in the 'reverse' direction (1 e HA 3
present in the donor, but absent in the recipient)
The number of bone marrow donor/recipient pairs investigated to date exceeds the
number presented earlier51 It must be remarked that this analysis showed a significant
associdtion between the HA 1,2,4 and 5 incompatibilities and the occurrence of GvHD
Now that we have investigated almost twice the number of donor/recipient pairs, the
latter correlation hardly reaehes a significant level (Table 3 5, p = 0 04) One of the
possible explanations for these observations IS that in at least four of the ten HA 1,2,4
and five identical donor/recipient combinations in the group of paüents suffenng from
chromc GvHD, wegenerated anti host CTL populations which could ιecognize minor Η
antigens other than HA 1,2,4 or 5 Moreover, assuming that HA 4 is indeed identical
to HA 5 and that HA 3 incompatibility does not play a role in the development of
GvHD, then we must reahze that we used only three minor Η antigen typing reagents
which obviously is not sufficient for a large number of donor/recipient combinations
The dichotomy among the minor Η antigens regarding their postulated difierent
roles in chnical bone marrow transplantation may possibly be explained by their
differential tissue distnbution To date, expenments carned out at the HPC level
(see previous discussion on the expression of the Η Υ antigen on HPC) support the
notion of differential expression of HA 3 versus the HA 1,2,4 and 5 antigemc
determinants (Voogt et al , ms in preparation) These studies may bring us closer
to understanding the different impacts of the HA antigens on the development of
GvHD and host versus graft disease (HvGD)
l'erspectives
At present our studies are extended to a posttransplant follow up time ot 2 years
As mentioned earlier, the cytotoxit and prohferative Variation of activity and the
phenotypic markers of the anti host Τ cell hnes of a senes of patients are presently
under study (van Eis et al , manuscnpt in preparation) Hopefully, thcse studies will
provide us with Information about the average number and the individual immuno
gemcity of the minor Η antigens, so that the most immunodorninant HAs can be
mapped actordmg to their impact in GvHD or rejectson
The HA specific CTI populations and CTL clones can be expandcd on a large
scalt, fro7en and, when preferred, used directly after thawing as typing reagents
providing in pnnciple, the clinician with results within 4 hours Prosoective donor
tvping for the most common and 'strongest' minor Η antigens may be helplul in
avoiding at least one of the obstacles to successful bone marrow transplantation This
might be especially true in such cases as when patients lack an HLA identical sibhng,
wheie more than one potential unrelated donor is available In this connection, it
would be helpful lf collaborative studies could be undertaken aimed at exchanging
and comparing Information and matenal between interested parties
Recognition of human minor Η antigens has been reported by several investigators
Elkins et dl S4 and Zier et al " desenbed tlit recognition of a human minot
alloantigen by lymphocytes denved from a multitransfused aplastic anaemia patient
Ihcy showed that the lymphocytes irom this in vivo sensitized patient, restirnulated
/// vitro using HLA mismatched stimulatoi cells, rccogmzed a non HLA antigen in
an MHC restneted fashion lesting of the paticnt's lymphocytes against a panel o(
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lymphocytes from unrelated individuals, and in famihes, indicated that the class I
molecule B7 was involved in the recognition of the minor Η antigen Tekolf and
Shaw5f demonstrated that in vivo pnming by pregnancy seemed to be sufficient to
generate cytotoxic Τ cells against a human minor Η antigen PBLs from a normal
femalc, after secondary in vitro Stimulation with cells from an HLA Α, Β , C and
D matched donor, showed strong cytotoxicity against a minor Η antigen in an HLA
restncted fashion The restncting molecule was again HLA B7 Also, after irreversible
rcjection of an HLA identical sibhng kidney allograft, CTLs directed against minor
Η antigens could be demonstiated in vitro 5 7 An elegant study was performed by
Sondel et al 5 8 who attempted to generate effector cells specific for leukaemic blasts
Despite the fact that indeed the effector cells recogmzed the leukaemic target cells
the non leukaemic lymphocytes from both parents of the patient were also lysed,
suggesting the lecognition of a minor Η antigen by these CTLs
However, a different approach for generating anti minor Η antigen specific
lesponses has been forwarded by Tekolf and Shaw 5 9 Their data indicated that minor
Η antigen speufic CTLs can be generated in vitro, without pnor in vivo priming,
by usmg a hmiting dilution System through which suppressor cells are diluted out
of the culture System Finally, Irle et al 6 0 descnbed anti minor Η antigen responses
posttransplantation of bone marrow, in essence this was an expenmental set up
comparable to ours The posttransplant CTL clones were directed against a rmnor
Η antigen whose recognition was HLA B7 restncted It IS of note that HLA B7, along
with HLA A2, appears to function well as a restncting antigen for minor Η antigens
Uns can be concluded from these studies and also from the preference of the Η Υ
uitigen tor HLA A2 and B7 as noted earher Moreover, among our new senes of
patients who are presently under investigation, HLA B7 in addition to A2 turned
out to be their favounte restncting molecules
The future use of more unielated marrow donors makes it obhgatory to know how
to distinguish between pernicious and harmless minor Η and major Η antigens With
Kgard to the former, one could Image that for example by mismatching foi HLA A2
ind selecting the serologically tross reactive HLA A28 antigen, no generation ol
HI Α A2 restncted anti minor Η antigen responses would be mduced Moreovei, with
tc^ard to the major histocompatibility anhgens, Identification ot the functionally
important molecules could lead practitally to more potential donors and would
hopefully diminish the chance of graft failure or GvHD Dispanties in the class II
n.mon
fl
 ° might be of particular interest because of theii role in activation of the
immune response although at least in a related Situation, there is no consensus on
ihc correlation between DP incompatibility and the oecurrence ot GvHD 6 4
HJTURE INVESTIGATIONS AND THEORETICAL CONSIDERATIONS
Which Cells Cause GvHD to Minor Η Antigens?
In the mouse, a vanety of studies have been carned out to explore the identity
tnd lunction of cells responsible for GvH leaction After the mitiating expenments
I Boak and Wilson'5 who showed that allogeneic lymphoid cell populations devoid
I donor Τ cells do not indute GvH disease, and thosc of Koingold and Spient1"
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who showed that by removmg mature Τ cells from the marrow, lethal GvHD across
minor Η barners could be prevented, the question of which donor Τ cells populations
are involved in the induction of GvHD was largely surveyed Α prehminary report
on the charactenzation of the cells involved in H-2 restncted GvH reactions showed
that both the Lyt 1 +2 and Lyt 1 2 f populations were involved 6 6 Recently, more
precise Information became available showing that Lyt 2+ Τ cells as well as L3T4 +
cells cause GvHD to minor Η antigen differences bl Moreover, the Τ cell subsets
lnitiating the GvHD may differ for each strain combination, a mixture of the
Lyt 2 f and L3T4 + Τ cell subsets, however, results in a severe form of GvHD 68 The
complexity of the immunological reactions lnitiating GvHD due to minor Η antigen
differences becomes even greater when we have to take into aecount Parkman's
findings that possibly different cellular mechanisms act m acute versus chrome
GvHD m Parkman charactenzed, by photypic and functional analysis at the clonal
level, the cells involved in acute GvHD and found that they were different from the
clones established dunng the chronic phase of the disease ω
In man, much less IS known about the charactenstics of the cells responsible
for lnitiating GvHD across non-MHC barners Dunng the last few years, several
investigators aimed at unmasking at least some of the minor Η antigen specific
cells playing a functional role in the course of the events after transplantation
of bone marrow Irle and colleagues70 studied the change, dunng in vitro cultunng,
of specific cytolytic activity patterns in a senes of minor Η antigen specific clones
obtamed from a marrow transplant patient after in vivo pnming Tilkin et al 71
desenbed a prohferative as well as cytotoxic mainly CD4 positive Τ cell hne, isolated
after transplantation of bone marrow, recogmzing a minor Η antigen in the
context of seif MHC class 11 The peeuhanty of the latter Τ cell hnc, which was of
donor ongin, is that lt showed autoreactivity and consequently might be of importance
in the reconstitution of the marrow and recovery of the immune svstem after
transplantation
As mentioned in earher sections, we recently gathered Information upon tht
composition and the function of the minor Η antigen specific effector cells at different
times after transplantation of bone marrow
Expression of Minor Η Antigens in the Skin
One of the affected organs dunng GvHD aftei bone marrow grafting is the skin
1 he assumplion that donor Τ cells are responsible for the epidermal lesions is generally
aeeepted in mouse and man In the mouse, Piguet et al 72 investigated the epidermal
lesions of GvHD ehcited by minor loci, whole MHC differences or a MHC class I
or II dilference alone They showed that donor Τ lymphocytes L3T4 ' Ly2 as well
as L3T4 I y 2' can ehcit the epidermal lesions in the vanous donor/recipient
combinations Similarly, epidermal damage resultmg from a marrow exchange over
a minoi Η antigen difference alone was reported earher n u These expenmental
animal ddta lead to the search for the target stiucture(s) causing the damage of the
epiderrms The antigens functionmg as Sites of attack could be for instance tissuc
iestncted histocompatibihty antigens such as the epidermal alloantigen Bpa 1 7S
In subsequent studies, Steinmuller et al demonstrated that by immune lymphocyte
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iransfer tests ι e injection of anti Epa 1 CTL clones, GvH lesions developed in Η 2k,
Epa 1 positive hosts 7 6
In man, Guyotat et al 7 7 carned out histological and immunopathological studies
on senal skin biopsies from patients after bone marrow transplantation Dermal and
epidermal Infiltration by CD8 + cells correlated with the seventy of GvHD The
pnmary Sites of attack in early GvH in the skin are the rete ndge keratinocytes 7 8
The antigenic target structures involved could be tissue specific antigens (expressed
on epithehal but not on lymphoid cells) hke in the studies of Tsoi et al 7 9 On the
other hand, minor Η antigen specific prohferative responses were also descnbed
Reinsmoen et al 8 0 took skin biopsies at the Site of the GvHD lesions, cultured them
and observed secondary prohferative responses in the presence of the patient's
pretransplant cells With regard to our own studies, we are presently explonng the
txpression of the minor Η antigens HA 1 to HA 5 on keratinocytes with the HA
spetific cytotoxic typing reagents Two most elegant approaches for detecting minor
Η antigen differences pnor to transplant were repoited by Vogelsang et al 8 I and
Bdgot et al 8 2 using a skin explant model and a mixed epidermal cell lymphocyte
ttaction respectively Both test Systems appeared to have predictive value, which
obviously IS very useful for donor selection The minor Η antigens inducing the
aetivities in the latter Systems remained, to my knowledge, umdentified
The Desired Side-effect of GvHD
We posed ourselves the question whether the posttransplant anti host C T L activity
ihat runs through this chapter hke a continuous thread might also be of advantage
lo ihe bone m a t r o w tiansplant recipients 7 D o the patients benefit fiom anti host C T L
)i_tivity' The hypothesis that post t ransplantat ion of bone marrow anti host C T L
lUivity may have a beneficial effect IS based on the aasurnption of the postulated
mti leukaemic potential as a 'desired' side effect oi the post bone marrow transplant
uimphcat ion GvH M 85 The current thoughts about GvL following bone marrow
nansplantat ion has been recently s u m m a n z e d by But tunni et al 8i)
In the third part of Fig 3-1 showing d o n o r Γ cells lesponsible for GvL, only
pi diminary results from our laboratory are availible The Information from the initial
L\pcnments can be s u m m a n z e d as follows fnst, some H A specific C T L seemed to
κ n.t with leukaemic cells, second, the H A antigen expression, as tested by quantitative
old target Inhibition expenments , can vary which might be depending on the
J i i l u e n t i a t i o n State of the leukaemic cells As ment ioned earher the host directed
I LÜI populations generated in patients suffenng from acute G v H D (woik in progress)
ind in patients without any chnical signs of G v H D are of course of pnme importance
toi the determination of their role in the GvL reaction Regalding the tew in vitro
inmiine studies in man to date on the mechamsms preventing leukaemia relapse after
I um. marrow transplantat ion, one detailed chnical and laboratory study by Sondell
>-t il deserves Special notice 87 These authors descnbed the lecurrence of the disease
II ψιΐβ the engraftment of donor marrow and the (secondary) tapabihty of the donor
IK to destroy the leukaemic cells Hopefully, such studies will facihtate the seaich
ι n the exact balance between GvH and GvL, yielding a higher etficacy for chnical
l'oni. marrow transplantat ion
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What are Minor Η Antigens*
The answer to this question can be either very short or extremely long, becau
nobody knows exactly Α vanety of proposals about the nature of the minor Η antige
suggest that they may be quite different from one another and quite different fro
the functions of the antigens of the MHC complex,88 they are probably membrat
bound and present on several tissues, lt IS unlikely that they are pnmanly concerm
wtth transplantation per se, they may be a diverse group of molecules participatir
in vanous cellular housekeeping functions and their antigenicity may come vei
inudentally, perhaps as a resuit of their expression in the plasma membrane,8-1 ο
minors are frankly mystenous entities, they fall to mduce an antibody response, the
are naturally processed fragments of polymorphic nucleoproteins that associate wil
MHC products % None of these utterances can yet be proved false As httle as vi
know now from the studies on human minor Η antigens, U is clear from our dal
that even the minor Η antigens which we detected by CTLs can be quite dilferei
from one anolher This is supported by the observation that the HA 3 antigen
determinant most probably differs from HA 1,2,4 and 5 in lts role in the developmei
of GvHD and by lts expression on HPC In general, no antibody responses again
minor Η antigens are observed except for H Y " The absence of these antibodic
falls in the same category as the 'MHC restncted plus X' antibodies Although th
number of antigen specific MHC restncted antibodies reported does not reat
overwhelming Icvels, the independent observations recently summan/ed, p strongl
suppoit the notion that they exist One of the previous proposals on minor Η antigei
furnishes food for reflection 'such mystenous entities' could well be proeessc
antigenic peptides from viruses In the framework of the multifaetonal aetiology ο
G v H D , " lt is of interest to examine our HA specific cellular ieagents for possibl
reactivity against virus infected target cells Finally, findings in the mouse by Colomb
et al g 4 add an extra dimension to the creative thoughts on the nature of minor l
antigens These authors ieported on the expression of new non Η 2 histocompatibilil
antigens (as defined by skm graft rejettion and by CTL sj through germ line msertio
of d gtne from retroviral origin
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